SenesTech Inc (SNES) — Titan Protect Analysis

SNES

SenesTech Inc

Basic Materials · ·

$1.53

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$9M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.36

Based on estimated future earnings — lower means cheaper

Rev Growth

+1.6%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-128.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$6.75

+341% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 2 analysts covering this stock

About SenesTech Inc

SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide; and Evolve, a soft bait containing the active ingredient, cottonseed oil that limits the reproduction of male and female rats beginning with the first breeding cycles following consumption. It also develops Evolve Mouse, a modified

https://www.senestech.com

Country: United States Employees: 23 Industry: Specialty Chemicals

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.216

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0431

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.642

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-52.7%

Historical annualised return based on price data

Max Drawdown

-82.1%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.19

Very low correlation to market moves

52W High

$6.24

75% below the year high

52W Low

$1.41

9% above the year low

Avg Volume

74,330

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.06

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

34.14

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

63.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-429.8%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$2M

Total revenue over the last 12 months

Net Income

$-6,781,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$6.75

Target Low

$3.50

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go